Pasithea Therapeutics Corp.(KTTA)

Biotechnology · Miami Beach, FL

$0.45-0.00 (-0.33%)

Delayed quote: Oct 6, 2026, 11:26 AM EDT

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T15:32:41.060Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:32:41.060Z.

Quote observation: 2026-10-06T15:26:31.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 15,150,110
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 45,663,782,000
TTM operating income · period ending 2026-06-30: -23,956,143

FMP input reference: b407bf9ab9426f7f8731c51b1e955f2cfcbe23f9f3e819a9868889fb687bb4da

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

KTTA EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

KTTA Competitors' EV/EBIT Ratio

KTTA

Pasithea Therapeutics Corp.

Current

Market Cap

$15.15M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KPTI

Karyopharm Therapeutics Inc.

vs KTTA

Market Cap

$14.96M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COCP

Cocrystal Pharma, Inc.

vs KTTA

Market Cap

$15.58M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OBX

Obsidian Therapeutics Inc.

vs KTTA

Market Cap

$14.44M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALLR

Allarity Therapeutics, Inc.

vs KTTA

Market Cap

$15.83M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PLSM

Pulsenmore Ltd. Ordinary Shares

vs KTTA

Market Cap

$14.24M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTXR

Citius Pharmaceuticals, Inc.

vs KTTA

Market Cap

$14.03M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BCDA

BioCardia, Inc.

vs KTTA

Market Cap

$16.22M

EV/EBIT Ratio

N/A

TTM Avg

33.55x

3Y Avg

33.49x

5Y Avg

33.49x

PASG

Passage Bio, Inc.

vs KTTA

Market Cap

$13.78M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INAB

IN8bio, Inc.

vs KTTA

Market Cap

$13.71M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Pasithea Therapeutics Corp. (KTTA)	$15.15M	N/A	N/A	N/A	N/A
Karyopharm Therapeutics Inc. (KPTI)vs ›	$14.96M	N/A	N/A	N/A	N/A
Cocrystal Pharma, Inc. (COCP)vs ›	$15.58M	N/A	N/A	N/A	N/A
Obsidian Therapeutics Inc. (OBX)vs ›	$14.44M	N/A	N/A	N/A	N/A
Allarity Therapeutics, Inc. (ALLR)vs ›	$15.83M	N/A	N/A	N/A	N/A
Pulsenmore Ltd. Ordinary Shares (PLSM)vs ›	$14.24M	N/A	N/A	N/A	N/A
Citius Pharmaceuticals, Inc. (CTXR)vs ›	$14.03M	N/A	N/A	N/A	N/A
BioCardia, Inc. (BCDA)vs ›	$16.22M	N/A	33.55x	33.49x	33.49x
Passage Bio, Inc. (PASG)vs ›	$13.78M	N/A	N/A	N/A	N/A
IN8bio, Inc. (INAB)vs ›	$13.71M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

KTTA EV/EBIT Ratio Metrics

KTTA Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics